Amphastar Pharma (AMPH) Tops Q4 EPS by 7c

Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of ($0.03), $0.07 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $55.9 million, versus $54.9 million reported last year.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Citigroup (C) Tops Q2 EPS by 42c
• UBS Reiterates Neutral Rating on Wingstop (WING), Expects Q2 to Reflect Pressured Sales Trends
• Piper Sandler lifts Halliburton, Patterson-UTI on stronger U.S. land outlook